2022
DOI: 10.1016/j.molmet.2022.101536
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacological inhibition of ALCAT1 mitigates amyotrophic lateral sclerosis by attenuating SOD1 protein aggregation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(4 citation statements)
references
References 65 publications
(127 reference statements)
0
4
0
Order By: Relevance
“…Inducible deletion of PTPMT1 in cerebella only causes a transient defect in adult mice that soon recover and appear grossly normal afterward [ 105 ], indicating that CL might play a less important role in the maintenance of brain functioning than in brain development. Intriguingly, the ablation of ALCAT1 activity in mice could either attenuate motor neuron dysfunction, inflammation, and muscle atrophy in a model of ALS [ 122 ], or inhibit MPTP-induced neurotoxicity, apoptosis, and motor deficits [ 40 ], indicating that ALCAT1 may be a therapeutic target for treating neuronal diseases. Regardless, the role of CL in neurons is not fully understood, and more studies should be performed in the future to investigate the effects of CL deficiency in different types of neurons and in distinct neurological disease models.…”
Section: CL In Neuronal Diseasesmentioning
confidence: 99%
“…Inducible deletion of PTPMT1 in cerebella only causes a transient defect in adult mice that soon recover and appear grossly normal afterward [ 105 ], indicating that CL might play a less important role in the maintenance of brain functioning than in brain development. Intriguingly, the ablation of ALCAT1 activity in mice could either attenuate motor neuron dysfunction, inflammation, and muscle atrophy in a model of ALS [ 122 ], or inhibit MPTP-induced neurotoxicity, apoptosis, and motor deficits [ 40 ], indicating that ALCAT1 may be a therapeutic target for treating neuronal diseases. Regardless, the role of CL in neurons is not fully understood, and more studies should be performed in the future to investigate the effects of CL deficiency in different types of neurons and in distinct neurological disease models.…”
Section: CL In Neuronal Diseasesmentioning
confidence: 99%
“…Our findings demonstrate that CMP3013 exhibits strong binding affinity to artificial IMMs that mimic the effects of pathogenic CL remodeling, including membranes containing 10% DLCL or reduced CL levels (from 20 to 5%) (Figure ). These results indicate that CMP3013 can rescue mitochondrial dysfunction resulting from CL peroxidation or remodeling, surpassing the limitations of gene expression attenuation . Moreover, these findings highlight the capability of CMP3013 to inhibit pathological CL remodeling in the IMM at nanomolar concentrations, an effect that cannot be accomplished by other known molecules.…”
Section: Discussionmentioning
confidence: 92%
“…These results indicate that CMP3013 can rescue mitochondrial dysfunction resulting from CL peroxidation or remodeling, surpassing the limitations of gene expression attenuation. 47 Moreover, these findings highlight the capability of CMP3013 to inhibit pathological CL remodeling in the IMM at nanomolar concentrations, an effect that cannot be accomplished by other known molecules.…”
Section: Discussionmentioning
confidence: 99%
“…However, copper can cause hydromineral regulatory malfunction, stressing or killing organisms, when the copper concentrations exceed the nutritional needs [4]. Disruptions in the homeostatic mechanisms of copper metabolism in brain are associated with human neurodegenerative disorders such as Menkes disease, Wilson's disease, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis [5,6]. In addition, copper displayed adverse effects on various aquatic organisms, including fish, algae, Daphnia, etc.…”
Section: Introductionmentioning
confidence: 99%